Heplisav-B (HepB-CpG) is a prescription vaccine used to help prevent infection from the hepatitis B virus. Heplisav-B is given as an injection into your muscle by a healthcare professional.

This study compared the effectiveness of Heplisav-B, a new hepatitis vaccine, vs. standard hepatitis B vaccines as a booster in previously vaccinated individuals. Study Approach: Researchers ...

Biotech has been hard hit, as one might expect, leaving many names in bargain territory. Learn why there are opportunities amidst market volatility.

Dynavax Technologies Corporation (Nasdaq: DVAX) ("Dynavax" or the "Company"), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today filed its ...

This study compared the effectiveness of Heplisav-B, a new hepatitis vaccine, vs. standard hepatitis B vaccines as a booster in previously vaccinated individuals. Study approach: Researchers ...

Der Vorstand von Dynavax bleibt dem Handeln im besten Interesse aller Aktionäre verpflichtet und ist bereit, den Dialog mit ihnen im Vorfeld der Jahreshauptversammlung 2025 fortzusetzen. Goldman Sachs ...

KLP Kapitalforvaltning AS bought a new position in shares of Dynavax Technologies Co. (NASDAQ:DVAX – Free Report) during the ...

Dynavax’s strategic focus includes expanding its market share for its hepatitis B vaccine, HEPLISAV-B, with projected revenues between $305 million and $325 million for 2025. The company is also ...